X4 PHARMACEUTICALS, INC Proceeds from Issuance of Debt
X4 PHARMACEUTICALS, INC (XFOR) reported Proceeds from Issuance of Debt of $694.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-11.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2019-03-11
- X4 PHARMACEUTICALS, INC proceeds from issuance of debt for the quarter ending 2017-12-31 was $9.00K.
- X4 PHARMACEUTICALS, INC proceeds from issuance of debt for the quarter ending 2017-09-30 was $19.00K.
- X4 PHARMACEUTICALS, INC proceeds from issuance of debt for fiscal 2017 was $694.00K, a 35.02% increase from fiscal 2016.
- X4 PHARMACEUTICALS, INC proceeds from issuance of debt for fiscal 2016 was $514.00K.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 6 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 12 month |
|---|---|---|---|---|
| 2017-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-11 | $28.00K derived: sum of 2 quarters · filed 2019-03-11 | $694.00K 10-K · filed 2019-03-11 | |
| 2017-09-30 | $19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $685.00K 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | $666.00K 10-Q · filed 2018-08-13 | |||
| 2016-12-31 | $514.00K 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |